Avi Leader1, Racheli Heffez Ayzenfeld, Michael Lishner, Efrat Cohen, David Segev, Doron Hermoni. 1. Departments of Internal Medicine A (A.L., R.H.A., M.L.), and Geriatric Medicine (R.H.A.), Meir Medical Center, Kfar-Saba 44281, Israel; Sackler Faculty of Medicine (A.L., R.H.A., M.L., D.H.), Tel-Aviv University, Tel-Aviv, Israel; and Department of Family Medicine (D.H.) in the Sharon-Shomron District (E.C., D.S.), Clalit Health Services, Israel.
Abstract
CONTEXT: The contemporary literature on the relationship between serum TSH levels and osteoporotic fractures in euthyroid individuals is limited by conflicting results and analyses conducted on a small number of fractures. OBJECTIVE: Our objective was to examine the association between the normal range of variation of TSH and the incidence of hip fractures in male and female euthyroid patients aged 65 years or older. DESIGN AND SETTING: We performed a population-based historical prospective cohort study within the Clalit Health Services population. PARTICIPANTS: Clalit Health Services members aged ≥65 years with at least 1 TSH measurement during the year 2004. We excluded patients with preexisting hip fracture, thyroid disease, malignancy, or chronic kidney disease. OUTCOME MEASURES: The primary outcome was hip fracture, and the secondary outcome was any other osteoporotic fracture. STATISTICAL ANALYSIS: Adjusted odds ratios comparing episodes of each outcome across 3 TSH groups (low, 0.35-1.6 mIU/L; intermediate, 1.7-2.9 mIU/L; high, 3-4.2 mIU/L) were generated using logistic regression models. RESULTS: The 14 325 included participants suffered from 514 hip fractures (mean follow-up, 102 ± 3 months). Women, but not men, in the lowest TSH group had a higher incidence of hip fractures (odds ratio = 1.28, 95% confidence interval = 1.03-1.59, P = .029) when compared with the intermediate group, after multivariate adjustment for age, comorbidities, and use of drugs affecting bone metabolism. There was no difference in hip fracture incidence between intermediate- and high-TSH groups. No association was found between TSH levels and other osteoporotic fractures. CONCLUSIONS: TSH levels within the lower normal range are associated with an increased risk of hip fractures in euthyroid women, but not men, aged 65 years and more.
CONTEXT: The contemporary literature on the relationship between serum TSH levels and osteoporotic fractures in euthyroid individuals is limited by conflicting results and analyses conducted on a small number of fractures. OBJECTIVE: Our objective was to examine the association between the normal range of variation of TSH and the incidence of hip fractures in male and female euthyroid patients aged 65 years or older. DESIGN AND SETTING: We performed a population-based historical prospective cohort study within the Clalit Health Services population. PARTICIPANTS: Clalit Health Services members aged ≥65 years with at least 1 TSH measurement during the year 2004. We excluded patients with preexisting hip fracture, thyroid disease, malignancy, or chronic kidney disease. OUTCOME MEASURES: The primary outcome was hip fracture, and the secondary outcome was any other osteoporotic fracture. STATISTICAL ANALYSIS: Adjusted odds ratios comparing episodes of each outcome across 3 TSH groups (low, 0.35-1.6 mIU/L; intermediate, 1.7-2.9 mIU/L; high, 3-4.2 mIU/L) were generated using logistic regression models. RESULTS: The 14 325 included participants suffered from 514 hip fractures (mean follow-up, 102 ± 3 months). Women, but not men, in the lowest TSH group had a higher incidence of hip fractures (odds ratio = 1.28, 95% confidence interval = 1.03-1.59, P = .029) when compared with the intermediate group, after multivariate adjustment for age, comorbidities, and use of drugs affecting bone metabolism. There was no difference in hip fracture incidence between intermediate- and high-TSH groups. No association was found between TSH levels and other osteoporotic fractures. CONCLUSIONS:TSH levels within the lower normal range are associated with an increased risk of hip fractures in euthyroid women, but not men, aged 65 years and more.
Authors: Carole E Aubert; Carmen Floriani; Douglas C Bauer; Bruno R da Costa; Daniel Segna; Manuel R Blum; Tinh-Hai Collet; Howard A Fink; Anne R Cappola; Lamprini Syrogiannouli; Robin P Peeters; Bjørn O Åsvold; Wendy P J den Elzen; Robert N Luben; Alexandra P Bremner; Apostolos Gogakos; Richard Eastell; Patricia M Kearney; Mari Hoff; Erin Le Blanc; Graziano Ceresini; Fernando Rivadeneira; André G Uitterlinden; Kay-Tee Khaw; Arnulf Langhammer; David J Stott; Rudi G J Westendorp; Luigi Ferrucci; Graham R Williams; Jacobijn Gussekloo; John P Walsh; Drahomir Aujesky; Nicolas Rodondi Journal: J Clin Endocrinol Metab Date: 2017-08-01 Impact factor: 5.958
Authors: Anne R Cappola; Alice M Arnold; Kendra Wulczyn; Michelle Carlson; John Robbins; Bruce M Psaty Journal: J Clin Endocrinol Metab Date: 2014-12-16 Impact factor: 5.958
Authors: Enrique Soto-Pedre; Moneeza K Siddiqui; Ify Mordi; Cyrielle Maroteau; Jimena Soto-Hernaez; Colin N A Palmer; Ewan R Pearson; Graham P Leese Journal: Eur Thyroid J Date: 2021-08-19
Authors: Tae Hyuk Kim; Ji Young Joung; Mira Kang; Sun Kyu Choi; Kyunga Kim; Ju Young Jang; Yoon Young Cho; Yong-Ki Min; Jae Hoon Chung; Sun Wook Kim Journal: PLoS One Date: 2015-12-17 Impact factor: 3.240